Cargando…

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

Natural killer (NK) cells are potent cytotoxic effector cells for cancer therapy and potentially for severe viral infections. However, there are technical challenges to obtain sufficient numbers of functionally active NK cells from a patient’s blood since they represent only 10% of the lymphocytes a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klingemann, Hans, Boissel, Laurent, Toneguzzo, Frances
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789404/ https://www.ncbi.nlm.nih.gov/pubmed/27014270 http://dx.doi.org/10.3389/fimmu.2016.00091

Ejemplares similares

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer
por: Nersesian, Sarah, et al.
Publicado: (2019)

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
por: Boissel, Laurent, et al.
Publicado: (2013)

Natural Killer Cell Line NK-92-Mediated Damage of Medically Important Fungi
por: Schmidt, Stanislaw, et al.
Publicado: (2021)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Natural Killer Cells for Cancer Immunotherapy: Pluripotent Stem Cells-Derived NK Cells as an Immunotherapeutic Perspective
por: Eguizabal, Cristina, et al.
Publicado: (2014)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
por: Zhang, Jianguang, et al.
Publicado: (2019)

Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines
por: Aquino-López, Arianexys, et al.
Publicado: (2017)

Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells
por: Sojka, Dorothy K, et al.
Publicado: (2014)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells
por: Villalba, Martin, et al.
Publicado: (2020)

What Fuels Natural Killers? Metabolism and NK Cell Responses
por: Gardiner, Clair M., et al.
Publicado: (2017)

Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
por: Carlsten, Mattias, et al.
Publicado: (2019)

Natural Killer Cell (NK-92MI)-Based Therapy for Pulmonary Metastasis of Anaplastic Thyroid Cancer in a Nude Mouse Model
por: Zhu, Liya, et al.
Publicado: (2017)

Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters
por: Parisi, Sarah, et al.
Publicado: (2022)

Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy
por: Murugan, Dhanashree, et al.
Publicado: (2022)

Selection and expansion of natural killer cells for NK cell-based immunotherapy
por: Becker, Petra S. A., et al.
Publicado: (2016)

Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity
por: Bernard, Nicole F., et al.
Publicado: (2017)

Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies
por: Carrega, Paolo, et al.
Publicado: (2017)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
por: Jochems, Caroline, et al.
Publicado: (2016)

Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
por: Seliger, Barbara, et al.
Publicado: (2022)

Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation
por: Park, Arum, et al.
Publicado: (2018)

Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy
por: Islam, Rasa, et al.
Publicado: (2021)

Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
por: Sun, Cheng, et al.
Publicado: (2015)

Aspergillus fumigatus responds to natural killer (NK) cells with upregulation of stress related genes and inhibits the immunoregulatory function of NK cells
por: Schneider, Andreas, et al.
Publicado: (2016)

Editorial: NK Cell-Based Cancer Immunotherapy
por: Borrego, Francisco, et al.
Publicado: (2016)

Editorial: NK cells in viral immunology and immunotherapy
por: Mulik, Sachin, et al.
Publicado: (2023)

Symptomatic Carotid Atherosclerotic Plaques Are Associated With Increased Infiltration of Natural Killer (NK) Cells and Higher Serum Levels of NK Activating Receptor Ligands
por: Bonaccorsi, Irene, et al.
Publicado: (2019)

Na(+)/H(+)-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells
por: Gong, Yao-Yu, et al.
Publicado: (2022)

Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy
por: Liu, Pingyi, et al.
Publicado: (2018)

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
por: Nikkhoi, Shahryar Khoshtinat, et al.
Publicado: (2023)

Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D
por: Gröschel, Carina, et al.
Publicado: (2017)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire
por: Meazza, Raffaella, et al.
Publicado: (2023)

NK Cell Metabolism and TGFβ – Implications for Immunotherapy
por: Slattery, Karen, et al.
Publicado: (2019)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)

“Natural Regulators”: NK Cells as Modulators of T Cell Immunity
por: Schuster, Iona S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f3lu4q2aegvae1msij1iehljob